Floatz logo

Xembify

Syndromic Agammaglobulinemia

Grifols Therapeutics LLCPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Syndromic Agammaglobulinemia cohort.

Asset / SponsorPhaseRating
Panzyga
Octapharma
Phase 3BB
Ciprofloxacin
Monash University
Phase 2/3B
CLAVULANIC ACID
Monash University
Phase 2/3B
Humax-Cd20
M.D. Anderson Cancer Center
Phase 2B
cc-5013
M.D. Anderson Cancer Center
Phase 2B
HUMAN IMMUNOGLOBULINS
Monash University
Phase 2/3B
Amoxicillin
Monash University
Phase 2/3B
Igpro20
Memorial Sloan Kettering Cancer Center
Phase 2CCC

Same molecule, other indications

Xembify is also rated in:

bacterial infectious diseaseDormant
B
Indicative ·
60 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
B
Indicative ·
60 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →